Abiraterone acetate, an inhibitor of adrenal androgen synthesis in "hormone refractory prostate cancer".

about

Abiraterone acetate, an inhibitor of adrenal androgen synthesis in "hormone refractory prostate cancer".

Item

http://www.wikidata.org/entity/Q41850941

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Abiraterone acetate, an inhibi ...... e refractory prostate cancer".

@en

type

Item

label

Abiraterone acetate, an inhibi ...... e refractory prostate cancer".

@en

prefLabel

Abiraterone acetate, an inhibi ...... e refractory prostate cancer".

@en

P1476

Abiraterone acetate, an inhibi ...... e refractory prostate cancer".

@en

P2093

Arun Kumar Goel

http://www.w3.org/2001/XMLSchema#string

Sudarsan De

http://www.w3.org/2001/XMLSchema#string

P2860

Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

Cancer statistics, 2009

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.

P304

43-45

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/0971-5851.81890

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21731216

http://www.w3.org/2001/XMLSchema#string

P921

abiraterone acetate

P932

3124990

http://www.w3.org/2001/XMLSchema#string